Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Maze Therapeutics, Inc. ( (MAZE) ) is now available.
On October 3, 2025, Maze Therapeutics, Inc. announced the appointment of Hervé Hoppenot as a Class II director and Chairman of the Board, effective October 6, 2025. Mr. Hoppenot, who has a significant background in the pharmaceutical industry, succeeds Dr. Charles Homcy, who will remain a director. This leadership change is expected to bring new strategic insights to the company, potentially impacting its operational and market positioning.
The most recent analyst rating on (MAZE) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Maze Therapeutics, Inc. stock, see the MAZE Stock Forecast page.
Spark’s Take on MAZE Stock
According to Spark, TipRanks’ AI Analyst, MAZE is a Neutral.
Maze Therapeutics shows strong financial performance with significant revenue and cash flow improvements, yet the negative equity presents a substantial risk. Technical indicators suggest potential weakness in stock momentum, and lack of valuation metrics prevents a comprehensive assessment. Overall, the stock’s strengths in financial growth are tempered by balance sheet risks and technical analysis concerns.
To see Spark’s full report on MAZE stock, click here.
More about Maze Therapeutics, Inc.
Average Trading Volume: 429,185
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.19B
See more insights into MAZE stock on TipRanks’ Stock Analysis page.